2026-02-03 → 2026-02-10
| Deal | Days Silent |
|---|---|
| AbbVie - Rinvoq | 17d |
| AbbVie - Vraylar | 17d |
| ACADIA Pharmaceuticals | Daybue | Rett syndrome | 17d |
| Alexion Pharmaceuticals - Ultomiris | 17d |
| Alkermes - Libalvi | 17d |
| Alnylam Pharmaceuticals | Amvuttra | ATTR-CM | 17d |
| Amgen Ultrarare US -Actimmune (CGD) | 17d |
| argenx US Vyvgart gMG | 17d |
| AstraZeneca | aHUS, PNH, HPP | UAE - Phase 2 | 17d |
| AstraZeneca | ATTR-CM | UAE - Phase 2 | 17d |
| AstraZeneca | PNH | UAE | 17d |
| Bayer | ATTR-CM | DE | 17d |
| Biogen - leqembi | 17d |
| Biogen US | 17d |
| BMS - US | 17d |
| BMS Breyanzi Patient Finder | 17d |
| BMS Portfolio Exploration Digital Health Team Patient Finder | 17d |
| Centene Patient Finder | 17d |
| Clinical University Childrens Hospital, Latvia (BUKS) | 14d |
| Eli Lilly and Company | 17d |
| EMD Serono | MS & Rare Disease | US | 17d |
| Genentach | Ocrevus | 17d |
| Genentech - Esbriet | 17d |
| Genentech - Xolair | 17d |
| Glenmark Pharma | 16d |
| GoodApple - Menopause RFP | 17d |
| HCF Hospitals Contribution Fund | 17d |
| Ipsen - Sohonos | 17d |
| Ipsen | Bylvay | 17d |
| J&J Immunology (Stelara) US - Phase 1 | 17d |
| J&J Immunology (Tremfya) US - Phase 1 | 17d |
| Jazz Pharma | 17d |
| Jazz Pharmaceuticals US- Xywav | 17d |
| Lilly Lilly Direct - Patient Finder | 17d |
| Lilly Zepbound OSA Ptient Finder | 18d |
| Novartis - Cosentyx (E2E Care Journey) | 17d |
| Novartis Fabhalta Patient Finder | 17d |
| Novartis Kesimpta Patient Finder | 17d |
| Pfizer | ATTR-CM | DE | 17d |
| Progyny | Endometriosis | US | 17d |
| Roche - Piasky | 17d |
| Roche LatAm | 17d |
| Roche | Neurology & Oncology | Global | 17d |
| Roche - Evrysdi | 17d |
| Takeda - Alunbrig | 17d |
| Takeda - Eohilia | 17d |
| Takeda - Oveporexton | 17d |
| TAKEDA | Psoriasis & Psoriatic Arthritis (Phase 3)| US | 17d |
| Trinity Life Sciences Exploration | 17d |
| VERTEX | AMKD | US | 17d |